Hanmi Pharmaceutical recorded the highest performance in 7 years since 2015. Its sales and operating profit were the largest since Q4 2015 when it signed a series of mega technology export deals, thanks to the success of its new combination drug and Beijing Hanmi.

On the 1st, Hanmi Pharmaceutical officially announced that its operating profit had increased 26.9% compared to the same period of the previous year to reach KRW 46.8 billion in Q3. Its sales revenue had also increased 12.9% to reach KRW 342.1 billion, and net profit by 11.5% to reach KRW 31.3 billion. The company’s cumulative operating profit had risen 44.2% compared to the same period of the previous year to reach KRW 119.2 billion, and its sa